Benign thyroid nodule unresponsive to radiofrequency ablation treated with laser ablation: a case report by Oddo, Silvia et al.
Oddo et al. Journal of Medical Case Reports  (2018) 12:127 
https://doi.org/10.1186/s13256-018-1628-9CASE REPORT Open AccessBenign thyroid nodule unresponsive to
radiofrequency ablation treated with laser
ablation: a case report
Silvia Oddo*, Margherita Balestra, Lara Vera and Massimo GiustiAbstract
Background: Radiofrequency ablation and laser ablation are safe and effective techniques for reducing thyroid nodule
volume, neck symptoms, and cosmetic complaints. Therapeutic success is defined as a nodule reduction > 50% between
6 and 12 months after the procedure, but a percentage of nodules inexplicably do not respond to thermal ablation.
Case presentation: We describe the case of a young Caucasian woman with a solid benign thyroid nodule
who refused surgery and who had undergone radiofrequency ablation in 2013. The nodule did not respond
in terms of either volume reduction or improvement in neck symptoms. After 2 years, given the patient’s
continued refusal of thyroidectomy, we proposed laser ablation. The nodule displayed a significant volume
reduction (− 50% from radiofrequency ablation baseline volume, − 57% from laser ablation baseline), and the
patient reported a significant improvement in neck symptoms (from 6/10 to 1/10 on a visual analogue scale).
Conclusions: We conjecture that some benign thyroid nodules may be intrinsically resistant to necrosis when one
specific ablation technique is used, but may respond to another technique. To the best of our knowledge, this is the
first description of the effect of performing a different percutaneous ablation technique in a nodule that does not
respond to radiofrequency ablation.
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Since 2010, practical guidelines have approved radiofre-
quency ablation (RFA) and laser ablation (LA) as pos-
sible therapeutic options for the treatment of benign
symptomatic thyroid nodules in patients who refuse thy-
roidectomy or in those with comorbidities that contra-
indicate surgery [1, 2]. RFA and LA are safe and
effective techniques for reducing nodule volume, neck
symptoms, and cosmetic complaints [3, 4].
Therapeutic success is defined as a nodule reduction >
50% from the baseline volume 6–12 months after the pro-
cedure and is reportedly achieved in 67% and 81% of cases
of LA and RFA, respectively, in 6- to 12-month follow-up
[3, 4]. However, for unknown reasons, a percentage of
nodules do not respond to thermal ablation.* Correspondence: dottoressaoddo@gmail.com
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first case in the literature of a benign thyroid nodule treated
unsuccessfully with RFA in which subsequent LA treat-
ment achieved a significant reduction in volume and neck
symptoms. This report suggests that practitioners of mini-
mally invasive thermal ablation can try different ablation
techniques on thyroid nodules that do not respond to RFA.
Case presentation
A 41-year-old Caucasian woman discovered the presence
of a mass on neck palpation. Her family history was
negative for thyroid illnesses, and she stated that she
had no past medical history. The woman was an office
worker, did not live or work in an iodine-poor area, and
reported having a good dietary intake of iodine. She nei-
ther smoked nor drank alcohol and was not taking any
medication. She was lean (body mass index 17 kg/m2),
and her blood pressure, heart rate, and temperature were
normal (100/65 mmHg, 76 beats/minute, and 36.2 °C,
respectively). A physical examination confirmed thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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which was mobile on swallowing. The results of her car-
diac, pulmonary, abdominal, and neurological examina-
tions were unremarkable.
The patient underwent an ultrasound (US) scan, which
showed a single, solid, isoechoic nodule of 12 ml
(anteroposterior × laterolateral × craniocaudal diameters
20 × 30 × 40 mm, respectively) in the right lobe of the
thyroid (Fig. 1a). She was symptomatic for neck discom-
fort, with a score of 6/10 on a visual analogue scale. Her
thyroid function was normal (thyroid-stimulating hor-
mone concentration 1.81 mIU/L, free T3 5.0 pmol/L,
free thyroxine 14.12 pmol/L); her calcitonin level was
normal (< 1 ng/L); and her thyroid autoimmunity was
negative (thyroid peroxidase antibodies 18 U/ml).
The patient underwent a fine-needle aspiration biopsy
(FNAB), which revealed a colloid nodular hyperplasia
with hyperplastic thyrocytes and fluid colloid (Thy2 ac-
cording to the British Thyroid Association). Because she
refused lobectomy for fear of surgery, we proposed RFA
of the nodule. After a second FNAB (Thy2 according to
the British Thyroid Association), a phoniatric evaluation,
which excluded anomalies of vocal cord motility, and an
electrocardiogram, which excluded arrhythmias as sug-
gested by the Korean consensus statement [5], a single
session of RFA was performed by means of transisthmic
access and moving-shot technique [5], with a delivered
energy of 41,868 J (3489 J/ml) in a day-hospital regimen.
RFA was performed by means of 7-cm, 18-gauge
electrodes with a 1-cm active tip, with the support of the
MyLabFive US system (Esaote, Genoa, Italy) with a 7.5-
MHz linear probe (LA523). The radiofrequencyFig. 1 Ultrasound images showing the thyroid nodule (a) at the baseline, (
laser ablationgenerator used was a Viva VRS01 RF system (STARmed,
Seoul, Korea), and the peristaltic pump used was an
R4S100 (STARmed, Seoul, Korea).
Before RFA, the patient underwent an intravenous in-
fusion for 30 minutes of ketorolac (20 mg) and raniti-
dine (50 mg) diluted in 100 ml of 0.9% saline solution.
Subsequently, intravenous ketorolac (40 mg) and raniti-
dine (50 mg) were administered in 500 ml of 0.9% saline
for about 5 hours (during and after thyroid RFA). Pre-
procedural local anesthesia with 2% lidocaine was car-
ried out at the puncture site. The procedure was well
tolerated by the patient, and no adverse events occurred.
After thyroid RFA, a compressive bandage and ice were
applied to the patient’s neck, and she received a domicil-
iary prescription for steroid administration (prednisone
25 mg for 3 days, 12.5 mg for 3 days, 6.25 mg for 3 days)
and gastric protection. At the time of the RFA, our oper-
ator had 1 year of experience with this technique.
At both the 6- and 12-month follow-up examinations,
the patient’s neck discomfort was seen to persist (Fig. 2a).
A physical examination confirmed the unchanged presence
of the soft mass, which was mobile on swallowing, in the
right portion of the neck. On a US scan, the nodule dis-
played only a modest and transitory volume reduction up
to the 6th month, followed by regrowth (Figs. 1b and 2a).
Twenty-four months after RFA, because the patient
again refused to undergo lobectomy, we proposed a sin-
gle session of LA. This was performed by the same oper-
ator, who had 1 year of experience with this technique,
by means of two 300-μm-diameter fibers inserted by
means of a 21-gauge Chiba needle (Elesta, Calenzano,
Italy) with one pull-back of 1 cm and a delivered energyb) 24 months after radiofrequency ablation, and (c) 12 months after
a b
Fig. 2 Changes in the volume of the nodule and in neck symptoms. (a) Changes in volume and in neck symptoms, as indicated on the visual
analogue scale, from baseline to 24 months after radiofrequency ablation. (b) Changes in volume and in neck symptoms, as indicated on the
visual analogue scale, from baseline of laser ablation (24 months after radiofrequency ablation) to 12 months after laser ablation. RFA
Radiofrequency ablation, VAS Visual analogue scale
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commercially available US scanner (EchoLaser X4®;
Esaote, Genoa, Italy) equipped with a 7.5-MHz linear
transducer (LA 332; Esaote, Genoa, Italy) with a 1064-
μm diode laser unit and an individual energy emission
setting and independent activation. The preprocedural
modalities were the same as for RFA.
The patient tolerated the procedure well, and no ad-
verse events occurred. At the time of LA, our operator
had 1 year of experience with this technique. The patient
reported a progressive improvement in neck symptoms
and cosmetic complaints, and follow-up examinations
showed a marked, progressive reduction in nodule vol-
ume (Figs. 1c and 2b). The patient’s thyroid function and
thyroid autoimmunity remained unchanged after RFA
and LA (Table 1).
Discussion
We report a case of a young woman who underwent
RFA for treatment of a symptomatic benign nodule ofTable 1: thyroid function and autoimmunity at each time-point of t
TSH f-T3
(mIU/L) (pmol/L)
(normal values 0.27-4.2) (normal values 2.76-7.07)
Baseline RFA 1.81 5.00
3rd month 1.60 4.98
6th month 1.43 5.20
12th month 1.57 5.05
24th month/Baseline LA 1.61 5.30
3rd month 1.47 5.12
6th month 1.36 4.97
12th month 1.89 5.00the right lobe of the thyroid after refusing thyroidec-
tomy. After 24 months, she underwent LA on the same
nodule because RFA had failed to reduce the volume of
the nodule and to alleviate her neck discomfort. To the
best of our knowledge, this is the first description of the
effect of performing a different percutaneous ablation
technique in a nodule that did not respond to RFA.
Both RFA and LA are percutaneous techniques, and
their efficacy in reducing thyroid nodule volume is re-
ported to be similar [6]. Therapeutic success (nodule
volume reduction > 50%) is achieved in the majority of
cases by both techniques [3, 4].
Some studies have identified factors that might predict
a good response to RFA, though these are controversial:
small volume (< 12 ml) of the nodule at baseline [7], the
absence of vascularization [8], the presence of a fluid
component [9], nonfunctioning status [10], and the pres-
ence of well-defined margins [4]. By contrast, Papini et al.
[3] found that baseline size, presence of goiter or US fin-
dings (such as fluid component, halo, vascularization, andhe study
f-T4 Calcitonin TPO-Abs
(pmol/L) (ng/L) (U/mL)
(normal values 11.97-21.88) (normal values <10) (normal values <100)
14.12 <1 18
15.30 - 19
14.35 - 25
15.07 - 15
14.78 - 26
15.03 - 30
14.99 - 24
15.12 - 19
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> 50% in thyroid nodules treated with LA. Our patient’s
thyroid nodule was < 13 ml, nonfunctioning, well-
defined, and free from vascularization; thus, there were
no parameters that could predict the inefficacy of RFA.
When therapy is not successful, another session of ab-
lation may be proposed; in the second session, the same
ablation procedure is generally performed [11]. This
choice is probably determined by the availability of only
LA or RFA in each center. In our center, however, we
had the possibility to perform both RFA and LA. We
chose to perform LA after unsuccessful RFA because, in
our cohort of patients, we had already observed two
cases in which the repetition of RFA had failed to yield
significant results in nodules that had previously been
treated with an unsuccessful RFA procedure. We there-
fore conjectured that certain nodules might be intrinsic-
ally resistant to necrosis when one ablation technique is
undertaken, but might respond to the other ablation
technique. Indeed, in our patient, the thyroid nodule,
which had not responded to a single session of RFA, dis-
played an optimal response to a single session of LA.
Differences in response to one or the other technique
might also depend on the operator’s experience. In our
patient, however, the same operator performed RFA and
LA and had the same amount of experience (1 year) in
performing both procedures. We therefore excluded the
possibility that the better response of the nodule to LA
might have been due to greater operator experience with
this technique.
Conclusions
In our opinion, LA may be a viable option in patients
with a thyroid nodule that does not respond to RFA and
who refuse surgery or have comorbidities that contra-
indicate it. It would be useful to conduct a study with a
large cohort of patients with an inefficient response to
one of these techniques who are subsequently treated
with the other technique.
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